Mentari Upsizes Pre-Merger Financing by $200M at a 52.8% Premium, Extending Runway to 2029
INM has more than doubled off its 52-week low of $0.575 on elevated volume (21× avg).
Summary
Mentari Therapeutics upsized its pre-merger private placement by $200 million at a premium, bringing total pre-closing financing to $490 million and extending the combined company's cash runway into 2029. InMed shareholders will own approximately 1.15% of the combined company.
Key Events · M&A and Partnerships · INM
-
$200M Upsize at Premium
Mentari added $200 million to its pre-closing financing, bringing the total to $490 million. The new shares are priced at 152.80% of the original round's per-share price, reflecting strong institutional demand.
-
Blue-Chip Investor Syndicate
New investors include Fairmount, ADAR1 Capital, Venrock, Janus Henderson, Blackstone, RTW Investments, Deep Track Capital, Vivo Capital, Commodore Capital, and BB Biotech.
-
Runway Extended to 2029
Proceeds fund operations into 2029, covering Phase 2a readouts for both PACAP-targeted lead programs (MT-001 and MT-002) and broader pipeline development.
-
InMed Ownership Diluted to ~1.15%
Pro forma combined company shares outstanding on an as-converted/exercised basis total ~601.2 million. Pre-merger InMed shareholders will own approximately 1.15% of the combined entity.
Analysis · INM · Life Sciences
Mentari Therapeutics has added $200 million to its pre-closing private placement, lifting the total to $490 million alongside the original $290 million. The new capital comes from a syndicate of blue-chip healthcare investors and is priced at a 52.8% premium to the original round — a strong signal of demand. With the proceeds, the combined company's runway now extends into 2029, funding both PACAP-targeted programs through Phase 2a readouts. For InMed shareholders, however, the dilution is stark: they will own just 1.15% of the combined entity, down from earlier estimates. The deal de-risks the merger financing and validates Mentari's pipeline, but leaves legacy InMed holders with a sliver of the upside.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 46.5% of the 301 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.48%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INM was trading at $1.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $0.58 to $2.75. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.